Spotlight: "Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study" (Singh, et al, 2025)
Observational study provides evidence regarding longer durability of generic IV ketamine compared to intranasal esketamine (Spravato).
Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study - PubMed
<span><b>Objective:</b> This study examines the durability (defined as time between treatments) of intravenous ketamine (IV-KET) and intranasal esketamine (IN-ESKET) for treatment-resistant depression (TRD), in a real-world clinical setting with repeated ketamine/esketamine maintenance therapy. <b>Methods</b></span> …
Balwinder Singh
Resultados a largo plazo en pacientes con depresión refractaria del tratamiento Recibiendo ketamina intravenosa y esketamina intranasal: Estudio observacional (Singh, et al, 2025)
El estudio observacional proporciona pruebas de una durabilidad más larga de la ketamina intravenosa genérica en comparación con la esketamina intranasal (Spravato).
